Clinical Core B

临床核心B

• 批准号: 8051773
• 负责人: DOUGLAS R GALASKO
• 金额: $ 95.7万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8051773
• 关键词: Activities of Daily Living; Affect; Age; Alzheimer' s Disease; American; Apolipoprotein E; Area; Autopsy; Behavior Therapy; Biological Specimen Banks; California; Clinical; Clinical Data; Clinical assessments; Cognitive; Communities; Consent; DNA; Data; Data Coordinating Center; Data Set; Dementia; Development; Diagnosis; Diagnostic; Disease; Education; Educational Materials; Elderly; Environment; Evaluation; Fostering; Frontotemporal Dementia; Funding; Future; Genotype; Goals; Grant; Hispanics; Information Dissemination; Instruction; Interdisciplinary Study; International; Laboratories; Lead; Lewy Body Disease; Neurological Nursing; Neuropsychological Tests; Parkinson Disease; Parkinson' s Dementia; Pathology; Patients; Performance; Pharmaceutical Preparations; Pilot Projects; Plasma; Principal Investigator; Procedures; Prospective Studies; Protocols documentation; Research; Research Personnel; Research Project Grants; Research Subjects; Resources; Risk; Site; Specimen; Testing; Therapeutic; Tissues; Training; Underserved Population; Work; clinical Diagnosis; cohort; data management; innovation; meetings; mild neurocognitive impairment; neuropathology; neuropsychological; programs; research clinical testing; statistics; tool

The Clinical Core has characterized, followed and provided subjects and data, and has collected and banked biological specimens that have contributed to much research progress in the past 25 years in areas such as early and accurate diagnosis of AD, tracking the course of dementia, and testing new treatment approaches for AD. The Specific Aims are: (1) Maintain and follow a panel of 400 well characterized English-speaking subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's Disease with Dementia (FDD), Mild Cognitive Impairment (MCI), and age- and education-matched healthy control subjects. (2) Maintain and follow a panel of 100 well characterized Spanish and English-speaking Hispanic subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's Disease with Dementia (PDD), Mild Cognitive Impairment (MCI), and age- and education-matched healthy control subjects through our Hispanic Initiative. (3) Maintain a high autopsy rate (i.e., greater than 70%). (4) Perform annual detailed and standardized nursing, neurological, and neuropsychological evaluations of all subjects. (5) Maintain and augment banks of plasma, DNA, and CSF from subjects with AD, MCI, and healthy controls. (6) Share clinical data with the National Alzheimer's Disease Data Coordinating Center (NACC) Uniform Data Set (UDS) and with investigators performing other multi-center analyses of clinical data. (7) Participate in projects with other ADCs (e.g., NACC), in ADNI, and in multi-center therapeutic drug trials for AD. (8) Refine and evaluate clinical and neuropsychological assessment procedures for accurate identification of MCI and the transition to AD in very mildly impaired subjects. (9) Refine and evaluate clinical, neuropsychological, and laboratory assessment procedures for the accurate differentiation of AD from DLB, PDD, Frontotemporal dementia (FTD), and other dementing disorders. (10) Coordinate activities such as autopsy procurement and education with other Cores. RELEVANCE (See instructions): AD affects millions of Americans with its risk growing exponentially with age. The AD Centers Program fosters research related to AD and non-AD dementias. The ADRC will enhance the performance of innovative research on AD and related topics, including research that may lead to potential disease modifying therapies or behavioral treatments. It will provide an environment and core resources to enhance research, foster professional and community training, and coordinate interdisciplinary research.

临床核心的表征，遵循和提供了主题和数据，并收集和库存 在过去25年中，在诸如 早期，准确的AD诊断，跟踪痴呆症的过程以及测试新治疗方法 对于广告。 具体目的是：（1）维护并遵循由400个具有英语的特色主题的面板 患有阿尔茨海默氏病（AD），有路易尸体的痴呆症（DLB），帕金森氏病和痴呆 （FDD），轻度认知障碍（MCI）以及年龄和教育匹配的健康对照受试者。 （2） 维护和关注由100个表征良好的西班牙语和英语的西班牙裔主题的小组 阿尔茨海默氏病（AD），有路易尸体（DLB），帕金森氏病（DLB），患有痴呆症（PDD）， 轻度认知障碍（MCI），以及通过我们的年龄和教育匹配的健康对照组 西班牙裔倡议。 （3）保持高尸检率（即大于70％）。 （4）执行年度详细 以及所有受试者的标准化护理，神经系统和神经心理学评估。 （5）维护和 来自具有AD，MCI和健康对照的受试者的血浆，DNA和CSF的增强库。 （6）分享 具有国家阿尔茨海默氏病数据协调中心（NACC）统一数据集的临床数据集 （UDS）和研究人员对临床数据进行其他多中心分析。 （7）参加 具有其他ADC（例如NACC），ADNI和AD多中心治疗药物试验的项目。 （8）精炼 并评估临床和神经心理评估程序，以准确鉴定MCI和 在非常轻度受损的受试者中向广告过渡。 （9）完善和评估临床，神经心理学， 和实验室评估程序，用于与DLB，PDD，额颞范围的准确分化 痴呆症（FTD）和其他痴呆症。 （10）协调尸检采购等活动 与其他核心教育。 相关性（请参阅说明）： 广告会影响数百万的美国人，其风险随着年龄的增长而成倍增长。广告中心计划 促进与AD和非AD痴呆有关的研究。 ADRC将提高 关于AD和相关主题的创新研究，包括可能导致潜在疾病的研究 修改疗法或行为疗法。它将提供一个环境和核心资源来增强 研究，培养专业和社区培训，并协调跨学科研究。